The effect of natural health products and traditional medicines on the activity of human hepatic microsomal-mediated metabolism of oseltamivir

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 13, Issue 1, 2010, Pages 43-55

  Liu, Rui ^a   Tam, Teresa W ^a   Mao, Jingqin ^a   Saleem, Ammar ^a   Krantis, Anthony ^a   Arnason, John T ^a   Foster, Brian C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; OSELTAMIVIR; UNCLASSIFIED DRUG; 4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; ANTIVIRUS AGENT; BIOLOGICAL PRODUCT; DRUG DERIVATIVE; PLANT EXTRACT; PRODRUG;

ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ACTIVITY; DRUG METABOLISM; ELECTROSPRAY; ENZYME INHIBITION; FLUOROMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INCUBATION TIME; PROTEIN EXPRESSION; TEMPERATURE DEPENDENCE; TRADITIONAL MEDICINE; CHINESE MEDICINE; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HERB DRUG INTERACTION; LIVER MICROSOME; MALE; METABOLISM; METHODOLOGY;

ANTIVIRAL AGENTS; BIOLOGICAL PRODUCTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FLUOROMETRY; HERB-DRUG INTERACTIONS; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MICROSOMES, LIVER; OSELTAMIVIR; PLANT EXTRACTS; PRODRUGS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 77955490366     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J3ZP42     Document Type: Article

References (16)

1. Shi, D., Yang, J., Yang, D., LeCluyse, E.L., Black, C., You, L., Akhlaghi, F., Yan, B. Anti-influenza prodrug oseltamivir is activated by carboxylesterase human carboxylesterase 1, and the activation is inhibited by antiplatelet agent clopidogrel. J Pharmacol Exp Ther, 319:1477-1484, 2006.
2. Yang, D., Pearce, R.E., Wang, X., Gaedigk, R., Wan, Y.J., Yan, B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem Pharmacol, 77:238-247, 2009.
3. Zhu, H.J., Patrick, K.S., Yuan, H.J., Wang, J.S., Donovan, J.L., DeVane, C.L., Malcolm, R., Johnson, J.A., Youngblood, G.L., Sweet, D.H., Langaee, T.Y., Markowitz, J.S. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet, 82:1241-1248, 2008.
4. He, G., Massarella, J., Ward, P. Clinical pharmacokinetics of the prodrug Oseltamivir and its active metabolite Ro 64-0802. Clin Pharmacokinet, 37:471-484, 1999.
5. Morimoto, K., Nakakariya, M., Shirasaka, Y., Kakinuma, C., Fujita, T., Tamai, I., Ogihara, T. Oseltamivir (Tamiflu) efflux transport at the bloodbrain barrier via P-glycoprotein. Drug Metab Dispos, 36:6-9, 2008.
6. Ogihara, T., Kano, T., Wagatsuma, T., Wada, S., Yabuuchi, H., Enomoto, S., Morimoto, K., Shirasaka, Y., Kobayashi, S., Tamai, I. Oseltamivir (TamifluTM) is a substrate of PEPT1. Drug Metab Dispos. 37:1676-1681, 2009.
7. Zhu, H.J., Markowitz, J.S. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos, 37(2):264-267, 2009.
8. Massarella, J.W., He, G., Dorr, A., Nieforth, K., Ward, P., Brown, A. The pharmacokinetics and tolerability of the oral neuraminidase inhibitor oseltamivir (Ro 64-0796/GS4104) in healthy adult and elderly volunteers. J Clin Pharmacol, 40:836-843, 2000.
9. Sweeny, D.J., Lynch, G., Bidgood, A.M., Lew, W., Wang, K.Y., Cundy, K.C. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metab Dispos, 28:737-741, 2000.
10. Zhu, H.J., Appel, D.I., Johnson, J.A., Chavin, K.D., Markowitz, J.S. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol, 77:1266-1272, 2009.
11. Zhu, H.J., Appel, D., Jiang, Y., Markowitz, J.S. Age and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos. 7:1819-1825, 2009.
12. Ose, A., Kusuhara, H., Yamatsugu, K., Kanai, M., Shibasaki, M., Fujita, T., Yamamoto, A., Sugiyama, Y. P-glycoprotein restricts the penetration of oseltamivir across the blood-brain barrier. Drug Metab Dispos, 36:427-434, 2008.
13. Izumi, Y., Tokuda, K., O'Dell, K., Zorumski, C., Narahashi, T. Synaptic and behavioral interactions of oseltamivir (Tamiflu) with neurostimulants. Hum Exp Toxicol, 27:911-9117, 2008.
14. Sørensen, J.M., Herb-therapeutic product, foodtherapeutic product, nutrient-therapeutic product, and therapeutic product-therapeutic product interactions: mechanisms involved and their medical implications. J Altern Complement Med, 8:293-308, 2002.
15. Leduc, C., Coonishish, J., Haddad, P.S., and Cuerrier, A. Plants used by the Cree nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: a novel approach in quantitative Ethnobotany. J Ethnopharmacol. 105:55-63, 2006.
16. Spoor, D. C. A., Martineau, L. C., Leduc, C., Benhaddou-Andaloussi, A., Meddah, B., Harris, C., et al. Selected plant species from the Cree pharmacopoeia of northern Quebec possess antidiabetic potential. Can J Physiol Pharmacol. 84, 847-858, 2006.